Repligen Corp (RGEN) stock
RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30132% above fair value
$172.67+10.49 (+6.47%)
Close on Nov 18, 2026Market cap $11.04BP/E –Yield –
Repligen total assets
Total assets on the balance sheet at the end of each period.
Repligen's total assets was $2.93B at Sep 30, 2026. For fiscal 2025 it was $2.95B, up 4.2% from the year before. Over ten years it grew 35.0% a year on average. The highest annual figure on record is $2.95B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.95B | +4.2% |
| FY2024 | Dec 31, 2024 | $2.83B | -0.1% |
| FY2023 | Dec 31, 2023 | $2.83B | +11.8% |
| FY2022 | Dec 31, 2022 | $2.53B | +7.3% |
| FY2021 | Dec 31, 2021 | $2.36B | +23.9% |
| FY2020 | Dec 31, 2020 | $1.90B | +35.9% |
| FY2019 | Dec 31, 2019 | $1.40B | +80.7% |
| FY2018 | Dec 31, 2018 | $774.62M | +4.2% |
| FY2017 | Dec 31, 2017 | $743.52M | +157.4% |
| FY2016 | Dec 31, 2016 | $288.91M | +97.6% |
| FY2015 | Dec 31, 2015 | $146.24M | +14.0% |
| FY2014 | Dec 31, 2014 | $128.29M | +8.1% |
| FY2013 | Dec 31, 2013 | $118.64M | +64.1% |
| FY2011 | Mar 31, 2011 | $72.29M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.93B | +0.1% |
| Q2 FY2026 | Jun 30, 2026 | $2.95B | +1.7% |
| Q1 FY2026 | Mar 31, 2026 | $2.93B | +2.8% |
| Q4 FY2025 | Dec 31, 2025 | $2.95B | +4.2% |
| Q3 FY2025 | Sep 30, 2025 | $2.92B | +3.3% |
| Q2 FY2025 | Jun 30, 2025 | $2.90B | +1.2% |
| Q1 FY2025 | Mar 31, 2025 | $2.85B | -0.1% |
| Q4 FY2024 | Dec 31, 2024 | $2.83B | -0.1% |
| Q3 FY2024 | Sep 30, 2024 | $2.83B | +12.2% |
| Q2 FY2024 | Jun 30, 2024 | $2.87B | +12.1% |
| Q1 FY2024 | Mar 31, 2024 | $2.85B | +12.0% |
| Q4 FY2023 | Dec 31, 2023 | $2.83B | +11.8% |
| Q3 FY2023 | Sep 30, 2023 | $2.52B | +2.4% |
| Q2 FY2023 | Jun 30, 2023 | $2.56B | +4.6% |
| Q1 FY2023 | Mar 31, 2023 | $2.55B | +6.9% |
| Q4 FY2022 | Dec 31, 2022 | $2.53B | +7.3% |
| Q3 FY2022 | Sep 30, 2022 | $2.46B | +9.9% |
| Q2 FY2022 | Jun 30, 2022 | $2.44B | +21.3% |
| Q1 FY2022 | Mar 31, 2022 | $2.38B | +23.7% |
| Q4 FY2021 | Dec 31, 2021 | $2.36B | +23.9% |
| Q3 FY2021 | Sep 30, 2021 | $2.24B | +51.8% |
| Q2 FY2021 | Jun 30, 2021 | $2.02B | +39.8% |
| Q1 FY2021 | Mar 31, 2021 | $1.93B | +37.0% |
| Q4 FY2020 | Dec 31, 2020 | $1.90B | +35.9% |
| Q3 FY2020 | Sep 30, 2020 | $1.48B | +7.1% |
| Q2 FY2020 | Jun 30, 2020 | $1.44B | +35.0% |
| Q1 FY2020 | Mar 31, 2020 | $1.41B | +76.3% |
| Q4 FY2019 | Dec 31, 2019 | $1.40B | +80.7% |
| Q3 FY2019 | Sep 30, 2019 | $1.38B | +80.9% |
| Q2 FY2019 | Jun 30, 2019 | $1.07B | +43.4% |
| Q1 FY2019 | Mar 31, 2019 | $797.92M | +7.4% |
| Q4 FY2018 | Dec 31, 2018 | $774.62M | +4.2% |
| Q3 FY2018 | Sep 30, 2018 | $762.13M | +3.8% |
| Q2 FY2018 | Jun 30, 2018 | $745.08M | +141.3% |
| Q1 FY2018 | Mar 31, 2018 | $743.25M | +155.7% |
| Q4 FY2017 | Dec 31, 2017 | $743.52M | +157.4% |
| Q3 FY2017 | Sep 30, 2017 | $734.24M | – |
| Q2 FY2017 | Jun 30, 2017 | $308.76M | – |
| Q1 FY2017 | Mar 31, 2017 | $290.63M | – |
| Q4 FY2016 | Dec 31, 2016 | $288.91M | – |
See a number that looks wrong?